TITLE

WEEK IN WASHINGTON

PUB. DATE
February 2014
SOURCE
BioWorld Insight;2/18/2014, Vol. 22 Issue 7, p6
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers information on the role of the U.S. Food and Drug Administration for missing out the opportunities to mitigate and proactively prevent drug shortages in the U.S., according to the reports of the U.S. Government Accountability Office (GAO).
ACCESSION #
94594253

 

Related Articles

  • FDA Update.  // Pharmaceutical Representative;May2010, Vol. 40 Issue 5, p11 

    The article focuses on a report issued by the U.S. Government Accountability Office (GAO) concerning the strategic planning and management of the Food and Drug Administration (FDA).

  • FDA safety effort necessary.  // Medical Marketing & Media;Feb2010, Vol. 45 Issue 2, p10 

    The article reports on the U.S. Government Accountability Office (GAO) study on the need for the Food and Drug Administration (FDA) to develop a comprehensive plan to prepare the Office of Surveillance and Epidemiology (OSE) to take over additional regulatory authorities from the Office of New...

  • FDA Questioned by Other Feds on High-Risk Devices. Reed, Vita // Orange County Business Journal;4/25/2011, Vol. 34 Issue 17, p65 

    The article reports that the approval of U.S. Food and Drug Administration (FDA) to certain high-risk medical devices such as pacemakers and hip joints, has been criticized by the Government Accountability Office (GAO), which states that the high-risk devices are approved without sufficient...

  • Action Needed to Improve Timeliness and Enhance Scope of FDA's Debarment and Disqualification Processes for Medical Product Investigators. Crosse, Marcia // GAO Reports;10/22/2009, preceding p1 

    The article reports on the study conducted by the U.S. Government Accountability Office (GAO) on the action needed to improve the Food and Drug Administration's (FDA) timely completion of debarment and disqualification processes clinical investigators. It states that investigators who have...

  • DRUG SAFETY: FDA Has Begun Efforts to Enhance Postmarket Safety, but Additional Actions Are Needed.  // GAO Reports;12/9/2009, preceding p1 

    The article discusses the findings of the U.S. Government Accountability Office (GAO) on the oversight of postmarket drug safety by the Food and Drug Administration (FDA). GAO claims that FDA has started to address concerns in its postmarket drug safety management. GAO also admires FDA's move to...

  • FOOD SAFETY: FDA Should Strengthen Its Oversight of Food Ingredients Determined to Be Generally Recognized as Safe (GRAS). Shames, Lisa // GAO Reports;3/5/2010, preceding p1 

    The article examines the oversight of the U.S. Food and Drug Administration on generally recognized as safe (GRAS) substances, by the Government Accountability Office (GAO). It was found that its oversight process does not ensure the safety of GRAS determinations. The agency does not issue...

  • FDA's Consideration of Evidence from Certain Clinical Trials. Crosse, Marcia // GAO Reports;8/30/2010, preceding p1 

    The article discusses a study conducted by the U.S. Government Accountability Office (GAO) on the Food and Drug Administration's (FDA's) decision for drug approval. The GAO examined the FDA's use of non-inferiority trial evidence to assess drug effectiveness by looking at new drug applications...

  • New Drug Development: Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts: GAO-07-49. Aronovitz, Leslie G. // GAO Reports;12/19/2006, p1 

    Drug development is complex and costly, requiring the testing of numerous chemical compounds for their potential to treat disease. Before a new drug can be marketed in the United States, a new drug application (NDA), which includes scientific and clinical data, must be approved by the Food and...

  • Medical Devices: Status of FDA's Program for Inspections by Accredited Organizations: GAO-07-157. Crosse, Marcia // GAO Reports;1/5/2007, p1 

    The Food and Drug Administration (FDA) inspects domestic and foreign establishments where U.S.-marketed medical devices are manufactured to assess compliance with FDA's quality system requirements for ensuring good manufacturing practices and other applicable requirements. The Medical Device...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics